Cargando…

Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases

BACKGROUND: Some articles suggest that using HbA1c alone for diabetes diagnosis is inappropriate. It requires considerable researches to explore the efficacy of HbA1c for diagnosing hyperglycemia in patients with pancreatic disease. METHODS: This study analyzed 732 patients, comprising of 331 withou...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guanhua, Zhang, Rui, Tan, Chunlu, Liu, Xubao, Yu, Lei, Chen, Yonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358977/
https://www.ncbi.nlm.nih.gov/pubmed/37484959
http://dx.doi.org/10.3389/fendo.2023.1208187
_version_ 1785075782034391040
author Chen, Guanhua
Zhang, Rui
Tan, Chunlu
Liu, Xubao
Yu, Lei
Chen, Yonghua
author_facet Chen, Guanhua
Zhang, Rui
Tan, Chunlu
Liu, Xubao
Yu, Lei
Chen, Yonghua
author_sort Chen, Guanhua
collection PubMed
description BACKGROUND: Some articles suggest that using HbA1c alone for diabetes diagnosis is inappropriate. It requires considerable researches to explore the efficacy of HbA1c for diagnosing hyperglycemia in patients with pancreatic disease. METHODS: This study analyzed 732 patients, comprising of 331 without pancreatic disease and 401 patients diagnosed with pancreatic diseases. All participants underwent the HbA1c assay and oral glucose tolerance test. Kappa coefficients were calculated to assess agreement between the HbA1c and glucose criteria. The receiver operating characteristic curve (ROC) was used to calculate the optimal HbA1c value. DeLong test was analyzed to compared the aera under curves (AUCs). RESULTS: There were 203 (61.3%) patients with NGT, 78 (23.6%) with prediabetes, and 50 (15.1%) with diabetes in patients without pancreatic diseases. In patients with pancreatic disease, 106 participants were diagnosed with NGT (36.4%), 125 with prediabetes (31.2%), and 130 with diabetes (32.4%). Patients with pancreatic disease exhibited elevated levels of bilirubin, transaminase enzymes, aspartate transaminase, high density lipoprotein cholesterol and total bile acid. The sensitivity and specificity of the HbA1c (6.5%) for diagnosing pancreatic diabetes were 60.8% (95% CI 52.3, 69.3) and 92.6% (95% CI 89.5, 95.7). In prediabetes, the sensitivity and specificity of HbA1c (5.7%) is 53.2% (44.3, 62.0) and 59.6 (51.5, 67.6). The optimal HbA1c value for diagnosing diabetes was 6.0% (AUC = 0.876, 95% CI 0.839, 0.906), with the sensitivity of 83.8% and the specificity of 76.8%. The optimal HbA1c value for the diagnosis of prediabetes was 5.8% (AUC = 0.617, 95% CI: 0.556, 0.675), with the corresponding sensitivity and specificity of 48.0% and 72.6% respectively. The combined tests (HbA1c, 6.0% or FPG, 7.0mmol/L) presented the sensitivity of 85.7% (95% CI 79.1, 91.3)and the specificity of 92.6% (95% CI 87.6, 97.3) in pancreatic diabetes. CONCLUSION: From our results, the recommended HbA1c by ADA criterion may not be sufficiently sensitive to diagnose hyperglycemia in pancreatic disease. The optimal value of 5.8% and 6.0% improved the accuracy for diagnosing prediabetes and diabetes and should be considered to be applied. Besides, we advocate the combination of HbA1c and FPG test for the diagnosis of diabetes in patients with pancreatic diseases.
format Online
Article
Text
id pubmed-10358977
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103589772023-07-21 Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases Chen, Guanhua Zhang, Rui Tan, Chunlu Liu, Xubao Yu, Lei Chen, Yonghua Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Some articles suggest that using HbA1c alone for diabetes diagnosis is inappropriate. It requires considerable researches to explore the efficacy of HbA1c for diagnosing hyperglycemia in patients with pancreatic disease. METHODS: This study analyzed 732 patients, comprising of 331 without pancreatic disease and 401 patients diagnosed with pancreatic diseases. All participants underwent the HbA1c assay and oral glucose tolerance test. Kappa coefficients were calculated to assess agreement between the HbA1c and glucose criteria. The receiver operating characteristic curve (ROC) was used to calculate the optimal HbA1c value. DeLong test was analyzed to compared the aera under curves (AUCs). RESULTS: There were 203 (61.3%) patients with NGT, 78 (23.6%) with prediabetes, and 50 (15.1%) with diabetes in patients without pancreatic diseases. In patients with pancreatic disease, 106 participants were diagnosed with NGT (36.4%), 125 with prediabetes (31.2%), and 130 with diabetes (32.4%). Patients with pancreatic disease exhibited elevated levels of bilirubin, transaminase enzymes, aspartate transaminase, high density lipoprotein cholesterol and total bile acid. The sensitivity and specificity of the HbA1c (6.5%) for diagnosing pancreatic diabetes were 60.8% (95% CI 52.3, 69.3) and 92.6% (95% CI 89.5, 95.7). In prediabetes, the sensitivity and specificity of HbA1c (5.7%) is 53.2% (44.3, 62.0) and 59.6 (51.5, 67.6). The optimal HbA1c value for diagnosing diabetes was 6.0% (AUC = 0.876, 95% CI 0.839, 0.906), with the sensitivity of 83.8% and the specificity of 76.8%. The optimal HbA1c value for the diagnosis of prediabetes was 5.8% (AUC = 0.617, 95% CI: 0.556, 0.675), with the corresponding sensitivity and specificity of 48.0% and 72.6% respectively. The combined tests (HbA1c, 6.0% or FPG, 7.0mmol/L) presented the sensitivity of 85.7% (95% CI 79.1, 91.3)and the specificity of 92.6% (95% CI 87.6, 97.3) in pancreatic diabetes. CONCLUSION: From our results, the recommended HbA1c by ADA criterion may not be sufficiently sensitive to diagnose hyperglycemia in pancreatic disease. The optimal value of 5.8% and 6.0% improved the accuracy for diagnosing prediabetes and diabetes and should be considered to be applied. Besides, we advocate the combination of HbA1c and FPG test for the diagnosis of diabetes in patients with pancreatic diseases. Frontiers Media S.A. 2023-07-06 /pmc/articles/PMC10358977/ /pubmed/37484959 http://dx.doi.org/10.3389/fendo.2023.1208187 Text en Copyright © 2023 Chen, Zhang, Tan, Liu, Yu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Chen, Guanhua
Zhang, Rui
Tan, Chunlu
Liu, Xubao
Yu, Lei
Chen, Yonghua
Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title_full Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title_fullStr Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title_full_unstemmed Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title_short Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases
title_sort optimal glycated hemoglobin a1c value for prediabetes and diabetes in patients with pancreatic diseases
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358977/
https://www.ncbi.nlm.nih.gov/pubmed/37484959
http://dx.doi.org/10.3389/fendo.2023.1208187
work_keys_str_mv AT chenguanhua optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases
AT zhangrui optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases
AT tanchunlu optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases
AT liuxubao optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases
AT yulei optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases
AT chenyonghua optimalglycatedhemoglobina1cvalueforprediabetesanddiabetesinpatientswithpancreaticdiseases